ATMP Symposium for Knowledge Exchange, Innovation, and Future Collaborations

Blog post by Carin Dahlberg, Scientific coordinator NextGenNK

On January 22, 2025, NextGenNK and CCRM Nordic hosted a mini-symposium at Karolinska Institutet, Campus Flemingsberg, with a focus on Advanced Therapy Medicinal Products (ATMP). The event aimed to foster networking within the ATMP field and provide insights into both academic and commercial advancements in Stockholm and Sweden.

NextGenNK and CCRM Nordic co-organized the mini-symposium to strengthen the development of ATMP by combining academic research with industrial expertise. During a half-day event, 14 presentations were delivered by representatives from academia, hospitals, and industry. Together, we aim to create a platform that facilitates innovation, production, and increased adoption of advanced therapies.

The event’s goal was to promote further collaboration and networking among researchers, clinicians, and industry partners, thereby supporting ongoing projects, contributing to the development of new initiatives, and increasing visibility for the ATMP field in Sweden. By bringing together experts and stakeholders, we strived to create a dynamic environment for knowledge sharing and future partnerships.

The mini-symposium was highly successful, with over 150 participants from more than 60 universities and companies. Attendees appreciated the opportunity to network and learn about the latest advancements in ATMP. The positive feedback highlights a strong interest in continued collaboration and development within this exciting field.

ATMP represents a rapidly growing sector in medicine, focusing on developing advanced therapies such as cell and gene therapies to treat previously incurable diseases. Progress in this area points toward more personalized treatments and innovative therapies that have the potential to revolutionize healthcare.

 Read more about the event here

Flemingsberg Science Foundation 2024 – New Opportunities Through Partnerships

As the year comes to an end, it is time to reflect and summarize our progress. We are now concluding year three of our four-year strategic period. Are we moving in the right direction to ensure that Flemingsberg becomes the obvious choice for establishments in southern Stockholm, offering a world-class innovation environment?

Cluster Engine Flemingsberg – ERDF Project for Growth in Life Science

Flemingsberg is taking a significant step towards establishing itself as a central player in Life Science with the launch of the “Cluster Engine Life Science Flemingsberg” project. The project has been granted funding from the European Regional Development Fund and aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. The total project budget is €10.8 million for the years 2025–2027.

BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development

As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.

Go to Top